晚期甲状腺癌仑伐替尼治疗期间的低钙血症:真实世界中的临床特征与管理
这项回顾性队列研究纳入意大利单中心25例接受仑伐替尼至少6个月的晚期甲状腺癌患者,平均治疗29±19个月。低钙血症发生率为24%(6/25,95%CI 9.36-45.13%),其中2例(8%)为≥3级,中位发生时间为用药后3个月(范围0.5-13个月)。作者结论认为该发生率高于注册试验报告的6.9%,建议在仑伐替尼治疗第一年监测血钙。
要点
- 25例晚期甲状腺癌患者中6例(24%)发生低钙血症,2例(8%)为≥3级。
- 低钙血症中位发生时间为开始仑伐替尼后3个月(范围0.5-13个月)。
- 发生与未发生低钙血症者在仑伐替尼起始/平均剂量及临床病理特征上无差异。
核心结论
- 在这相对较小的队列中观察到低钙血症发生率为24%,高于注册试验报告的6.9%。
- 本队列中低钙血症可由甲状旁腺激素(PTH)依赖和非PTH依赖两种机制解释。
- 作者强烈建议在仑伐替尼治疗第一年监测血钙,因为低钙血症可能严重。
- 作者认为需要更多研究来证实这些发现并为晚期甲状腺癌患者接受仑伐替尼治疗时低钙血症的可能危险因素提供信息。
研究设计与样本
- 回顾性队列研究,纳入意大利单中心连续接受仑伐替尼治疗至少6个月的晚期甲状腺癌患者。
- 共纳入25例患者,平均治疗29±19个月(范围6-68个月)。
- 治疗期间评估磷钙代谢。
主要发现
- 25例中6例发生低钙血症(24% [95% CI 9.36-45.13%]),其中2例(8%)为≥3级,6例中4例(67%)复发。
- 低钙血症中位发生时间为开始仑伐替尼后3个月(范围0.5-13个月)。
- 发生与未发生低钙血症的患者在仑伐替尼起始剂量或平均剂量以及临床病理特征方面均无差异。
- 低钙血症危象时,2例≥3级低钙血症患者血镁低且PTH水平低或不恰当地正常;3例2级低钙血症患者中2例存在继发性甲状旁腺功能亢进。
- 低钙血症多数经口服钙补充管理,但高达10%的患者需要静脉钙治疗并暂时停用仑伐替尼。
临床怎么用
- 作者强烈建议在仑伐替尼治疗第一年监测血清钙水平,因为低钙血症可能严重。
- 低钙血症多数采用口服钙补充管理,部分患者需要静脉钙治疗并暂时停用仑伐替尼。
局限性
- 本研究为回顾性队列研究且样本量相对较小(25例)。
- 作者指出需要更多研究来证实这些发现并为仑伐替尼治疗晚期甲状腺癌患者低钙血症的可能危险因素提供信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Several toxicities are recorded during treatment of advanced thyroid cancer (TC) with antiangiogenic drugs, including lenvatinib (LEN). Hypocalcemia was reported in registration studies, but little data are available from real-life cohorts. The aim of our study was to describe the incidence, characteristics, and the management of hypocalcemia in patients on LEN treatment. Methods: This is a retrospective cohort study of consecutive patients with advanced TC, treated with LEN for at least six months at a single tertiary center in Italy. Phosphocalcic metabolism was evaluated during treatment. Results: We included 25 patients treated for a mean of 29 ± 19 months (range 6-68 months). Hypocalcemia occurred in 6 of the 25 patients (24% [95% confidence interval 9.36-45.13%]), being of grade ≥3 in 2 of the 25 patients (8%), and recurrent in 4 of 6 patients (67%). The median time to hypocalcemia onset was 3 months (range 0.5-13 months) from starting LEN. No differences were found between patients who developed or not hypocalcemia regarding either starting/mean dose of LEN or clinicopathological characteristics. During the hypocalcemic crisis, the 2 patients with grade ≥3 hypocalcemia had low magnesium and low or inappropriately normal parathormone (PTH) levels, while 2 of 3 patients with grade 2 hypocalcemia had a secondary hyperparathyroidism. Hypocalcemia was managed with calcium oral supplementation in most cases, although up to 10% of patients required intravenous calcium treatment and transient LEN withdrawal. Conclusions: In this relatively small cohort, we observed an incidence of hypocalcemia of 24%, which is higher than that reported in the registration trial (6.9%). Both PTH-dependent and PTH-independent mechanisms explained hypocalcemia in the present cohort. Monitoring of serum calcium levels is strongly advised during the first year of LEN treatment, as hypocalcemia may be severe. More research is needed to confirm our findings and inform possible risk factors for hypocalcemia in advanced TC patients treated with LEN.
引用
- De Leo S, Trevisan M, Colombo C, et al. Hypocalcemia During Lenvatinib Treatment for Advanced Thyroid Cancer: Clinical Features and Management in a Real-Life Setting. Thyroid. 2022. PMID: 36326203. doi:10.1089/thy.2022.0439
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。